35 completed, 7 terminated, 5 active not recruiting, 4 recruiting. 40 Phase 1, 13 Phase 3, 12 Phase 2, 1 Phase 4.
Follow Bio-Thera Solutions: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis BAT4406F, Placebos - Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 192 | 2025-10-26 | 2026-04-03 |
| A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants BAT3306, US-Keytruda® - Carcinoma, Non-Small-Cell Lung | Phase 1 | Active not recruiting | Bio-Thera Solutions | 160 | 2025-10-14 | 2026-09-02 |
| A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer BAT8006 for Injection - Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Withdrawn | Bio-Thera Solutions | 2025-01-31 | 2026-01-07 | |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema BAT5906 injection, Lucentis - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Bio-Thera Solutions | 406 | 2024-10-09 | 2026-04-07 |
| A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC BAT3306, EU-Keytruda®, US-Keytruda® - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Bio-Thera Solutions | 162 | 2024-07-19 | 2025-12-02 |
| A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors BAT8010 for Injection, BAT1006 for Injection - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Bio-Thera Solutions | 218 | 2024-05-08 | 2026-09-30 |
| A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors BAT8008 injection, BAT1308 injection - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Bio-Thera Solutions | 112 | 2024-04-12 | 2026-10-02 |
| BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer carboplatin, Paclitaxel, Recombinant humanized anti-PD-1 monoclonal antibody injection - Endometrial Cancer | Phase 2 / Phase 3 | Terminated | Bio-Thera Solutions | 5 | 2024-04-09 | 2025-08-14 |
| Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients BAT4706 Injection, BAT1308 Injection - Advanced Solid Tumor | Phase 1 | Completed | Bio-Thera Solutions | 35 | 2024-03-06 | 2026-10-15 |
| BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer Recombinant humanized anti-PD-1 monoclonal antibody injection, Cisplatin, Bevacizumab Injection - Cervical Cancer | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 526 | 2023-12-13 | 2025-02-10 |
| Evaluate the Safety, Tolerability of BAT6026 Monoclonal antibody BAT6026, sodium chloride injection - Dermatitis, Atopic | Phase 1 / Phase 2 | Active not recruiting | Bio-Thera Solutions | 33 | 2023-11-09 | 2026-10-02 |
| Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection, Pembrolizumab injection - Healthy Male Subjects | Phase 1 | Completed | Bio-Thera Solutions | 59 | 2023-11-05 | 2024-10-30 |
| A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects BAT1806 prefilled subcutaneous injection/RoActemra® (from EU) - Healthy Men | Phase 1 | Completed | Bio-Thera Solutions | 300 | 2023-08-29 | 2025-05-29 |
| A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders BAT4406F Injection, BAT4406F Placebos - Optic Neuromyelitis Spectrum Disease | Phase 2 | Active not recruiting | Bio-Thera Solutions | 162 | 2023-08-01 | 2026-10-02 |
| A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection BAT1706 Injection - Healthy Men | Phase 1 | Completed | Bio-Thera Solutions | 38 | 2023-06-15 | 2026-10-01 |
| Clinical Study of Stage IV Psoriasis in Children With Geleli Plaque Psoriasis | Completed | Bio-Thera Solutions | 80 | 2023-04-05 | 2026-03-13 | |
| Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients BAT8010 for Injection - Advanced or Metastatic Solid Tumors | Phase 1 | Completed | Bio-Thera Solutions | 23 | 2023-02-10 | 2026-03-30 |
| To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors BAT8007 for injection - Advanced Solid Tumors | Phase 1 | Terminated | Bio-Thera Solutions | 93 | 2023-01-17 | 2026-04-13 |
| Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection BAT8008 for Injection - Advanced Solid Tumors | Phase 1 | Recruiting | Bio-Thera Solutions | 182 | 2022-11-30 | 2026-02-09 |
| Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients BAT2306, EU-approved Cosentyx - Plaque Psoriasis | Phase 3 | Completed | Bio-Thera Solutions | 502 | 2022-10-26 | 2025-04-23 |
Showing 20 of 57. Sign in to see all of them.
Arthritis, Psoriatic (3) · Arthritis, Rheumatoid (2) · COVID-19 (2) · Carcinoma, Non-Small-Cell Lung (2) · Macular Degeneration (2) · Psoriasis (2) · Asthma (1) · Dermatitis, Atopic (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glomerulosclerosis, Focal Segmental (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Nephrosis, Lipoid (1) · Neuromyelitis Optica (1)
Injections (15) · Carboplatin (4) · Paclitaxel (3) · pembrolizumab (3) · tocilizumab (3) · Ranibizumab (2) · Ustekinumab (2) · secukinumab (2) · Adalimumab (1) · BAT2022 (1) · Bevacizumab (1) · Capecitabine (1) · Cisplatin (1) · Lapatinib (1) · Pemetrexed (1)
China (50) · Australia (3) · Mexico (1) · New Zealand (1) · South Africa (1) · Turkey (Türkiye) (1) · Ukraine (1) · United States (1)
Yanhua Ding (3) · Youxin Chen (3) · Li Zhang, M.D, Ph.D (2) · Min Zheng (2) · Shusen Wang, M.D. (2) · Wei Hu, Ph.D (2) · Weiyong Li (2) · Xiaoling Luo, Doctor (2) · Xiaorong Dong, Dr. (2) · Abhijit Pal, M.D, Ph.D (1) · Aiyu Lin, Doctor (1) · Bo Hu, Doctor (1) · Chaohe Wang (1) · Chris Wynne, Medical Doc (1) · Chunfeng Liu, Doctor (1)
PMID 40198544, PMID 31016568, PMID 33241960, PMID 33569002, PMID 36417156, PMID 38258678, PMID 39244595, PMID 39592888, PMID 40786037, PMID 41069221, PMID 42021476, PMID 42372782, PMID 42615128, PMID 42701929